| P/E (FY) | 38.3 | Sales (TTM) | $2.78B |
| Earnings (TTM) | $491.5M | ROE | 70.23% |
| Net Margin | 17.83% | ROIC | 753.29% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 28.04% | Sales Growth 3Y | 20.12% |
Medpace Holdings provides clinical research-based drug and medical device development services across North America, Europe, Asia, South America, Africa, and Australia. It supports the clinical development process from Phase I through Phase IV with services including study design, central laboratory, project management, regulatory affairs, clinical monitoring, data management, and pharmacovigilance, as well as bio-analytical laboratory, imaging, and electrocardiography support.
| Market Cap | $16.33B | Trading Days | 2499 |
| 52W High | 677.90 |
| 52W Low | 373.00 |
| % Off High | −13.71% |
| YTD | 4.14% | 1Y | 30.59% |
| 3Y | 131.04% | 5Y | 232.90% |
| Since incept. (ann.) | 35.77% |
Oncology 30% · Metabolic 29% · Other 16% · Central Nervous System 10% · …
| Ann. Volatility (1Y) | 44.91% | Ann. Volatility (3Y) | 53.10% |
| Sharpe (1Y) | 0.82 | Sharpe (3Y) | 0.77 |
| Max Drawdown (1Y) | −36.61% | Max Drawdown (3Y) | −39.38% |
| Beta (3Y, vs SPY) | 0.74 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $11.31B | — |
| INCY | INCYTE CORP | $25.39B | 19.8 |
| IQV | IQVIA HOLDINGS INC. | $41.32B | 31.6 |
| ABSI | Absci Corp | $1.08B | — |
| NRC | NRC HEALTH | $412.4M | 35.6 |
| OABI | OmniAb, Inc. | $282.7M | — |
| MXCT | MAXCYTE, INC. | $108.2M | — |
| ONMD | OneMedNet Corp | $35.0M | — |
| BIAF | bioAffinity Technologies, Inc. | $2.7M | — |
| FOXO | FOXO TECHNOLOGIES INC. | — | — |
| BBIO | BridgeBio Pharma, Inc. | $16.36B | — |
| JAZZ |
| Jazz Pharmaceuticals plc |
| $16.06B |
| — |